Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Risankizumab in moderate-to-severe plaque psoriasis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risankizumab in moderate-to-severe plaque psoriasis.
Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Arthralgia
Clinical Trials as Topic
Headache
Humans
Interleukin-23 Subunit p19
Psoriasis
Respiratory Tract Infections
Severity of Illness Index
Treatment Outcome
authors with profiles
Kenneth Gordon